Cargando…

Evaluation of pseudoephedrine pharmacy sales before and after mandatory recording requirements in Western Australia: a case study

BACKGROUND: A community pharmacy real-time electronic recording program, ProjectSTOP, enables Australian community pharmacists to verify pseudoephedrine requests. In Western Australia the program was available for voluntary use from April 2007 and became mandatory November 2010. This case study expl...

Descripción completa

Detalles Bibliográficos
Autores principales: Hattingh, Hendrika Laetitia, Varsani, Janki, Kachouei, Leila Ataei, Parsons, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5004257/
https://www.ncbi.nlm.nih.gov/pubmed/27577258
http://dx.doi.org/10.1186/s13011-016-0075-0
_version_ 1782450768471654400
author Hattingh, Hendrika Laetitia
Varsani, Janki
Kachouei, Leila Ataei
Parsons, Richard
author_facet Hattingh, Hendrika Laetitia
Varsani, Janki
Kachouei, Leila Ataei
Parsons, Richard
author_sort Hattingh, Hendrika Laetitia
collection PubMed
description BACKGROUND: A community pharmacy real-time electronic recording program, ProjectSTOP, enables Australian community pharmacists to verify pseudoephedrine requests. In Western Australia the program was available for voluntary use from April 2007 and became mandatory November 2010. This case study explores the effectiveness of the program by reviewing the total requests for pseudoephedrine products, and the proportion of requests which were classified as ‘denied sales’ before and after mandatory implementation. Seasonal and annual trends in these measures are also evaluated. METHODS: ProjectSTOP data recordings for Western Australia pharmacies between 1 December 2007 and 28 February 2014 were analysed. Data included a de-identified pharmacy number and date of each pseudoephedrine product request. The total number of requests and sale classification (allowed, denied, safety, or not recorded) were calculated for each month/pharmacy. The potential influence of mandatory reporting using ProjectSTOP was investigated using a Regression Discontinuity Design. Correlations between sales from the same pharmacy were taken into account by classifying the pharmacy number as a random effect. The main effects of year (continuous variable), and season (categorical variable) were also included in the model. RESULTS: There was a small but steady decline in the total requests for pseudoephedrine per month per 100,000 population (per pharmacy) from the time of mandatory reporting. The number of denied sales showed a steady increase up until mandatory reporting, after which it showed a significant decline over time. Total sales were heavily influenced by season, as expected (highest in winter, least in summer). The seasonal pattern was less pronounced for denied sales, which were highest in winter and similar across other seasons. The pattern over time for safety sales was similar to that for denied sales, with a clear change occurring around the time of mandatory reporting. CONCLUSION: Results indicate a decrease in pseudoephedrine product requests in Western Australia community pharmacies. Findings suggest ProjectSTOP has been successful in addressing suspicious sales and potential diversion however ongoing data review is recommended.
format Online
Article
Text
id pubmed-5004257
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-50042572016-08-31 Evaluation of pseudoephedrine pharmacy sales before and after mandatory recording requirements in Western Australia: a case study Hattingh, Hendrika Laetitia Varsani, Janki Kachouei, Leila Ataei Parsons, Richard Subst Abuse Treat Prev Policy Research BACKGROUND: A community pharmacy real-time electronic recording program, ProjectSTOP, enables Australian community pharmacists to verify pseudoephedrine requests. In Western Australia the program was available for voluntary use from April 2007 and became mandatory November 2010. This case study explores the effectiveness of the program by reviewing the total requests for pseudoephedrine products, and the proportion of requests which were classified as ‘denied sales’ before and after mandatory implementation. Seasonal and annual trends in these measures are also evaluated. METHODS: ProjectSTOP data recordings for Western Australia pharmacies between 1 December 2007 and 28 February 2014 were analysed. Data included a de-identified pharmacy number and date of each pseudoephedrine product request. The total number of requests and sale classification (allowed, denied, safety, or not recorded) were calculated for each month/pharmacy. The potential influence of mandatory reporting using ProjectSTOP was investigated using a Regression Discontinuity Design. Correlations between sales from the same pharmacy were taken into account by classifying the pharmacy number as a random effect. The main effects of year (continuous variable), and season (categorical variable) were also included in the model. RESULTS: There was a small but steady decline in the total requests for pseudoephedrine per month per 100,000 population (per pharmacy) from the time of mandatory reporting. The number of denied sales showed a steady increase up until mandatory reporting, after which it showed a significant decline over time. Total sales were heavily influenced by season, as expected (highest in winter, least in summer). The seasonal pattern was less pronounced for denied sales, which were highest in winter and similar across other seasons. The pattern over time for safety sales was similar to that for denied sales, with a clear change occurring around the time of mandatory reporting. CONCLUSION: Results indicate a decrease in pseudoephedrine product requests in Western Australia community pharmacies. Findings suggest ProjectSTOP has been successful in addressing suspicious sales and potential diversion however ongoing data review is recommended. BioMed Central 2016-08-30 /pmc/articles/PMC5004257/ /pubmed/27577258 http://dx.doi.org/10.1186/s13011-016-0075-0 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Hattingh, Hendrika Laetitia
Varsani, Janki
Kachouei, Leila Ataei
Parsons, Richard
Evaluation of pseudoephedrine pharmacy sales before and after mandatory recording requirements in Western Australia: a case study
title Evaluation of pseudoephedrine pharmacy sales before and after mandatory recording requirements in Western Australia: a case study
title_full Evaluation of pseudoephedrine pharmacy sales before and after mandatory recording requirements in Western Australia: a case study
title_fullStr Evaluation of pseudoephedrine pharmacy sales before and after mandatory recording requirements in Western Australia: a case study
title_full_unstemmed Evaluation of pseudoephedrine pharmacy sales before and after mandatory recording requirements in Western Australia: a case study
title_short Evaluation of pseudoephedrine pharmacy sales before and after mandatory recording requirements in Western Australia: a case study
title_sort evaluation of pseudoephedrine pharmacy sales before and after mandatory recording requirements in western australia: a case study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5004257/
https://www.ncbi.nlm.nih.gov/pubmed/27577258
http://dx.doi.org/10.1186/s13011-016-0075-0
work_keys_str_mv AT hattinghhendrikalaetitia evaluationofpseudoephedrinepharmacysalesbeforeandaftermandatoryrecordingrequirementsinwesternaustraliaacasestudy
AT varsanijanki evaluationofpseudoephedrinepharmacysalesbeforeandaftermandatoryrecordingrequirementsinwesternaustraliaacasestudy
AT kachoueileilaataei evaluationofpseudoephedrinepharmacysalesbeforeandaftermandatoryrecordingrequirementsinwesternaustraliaacasestudy
AT parsonsrichard evaluationofpseudoephedrinepharmacysalesbeforeandaftermandatoryrecordingrequirementsinwesternaustraliaacasestudy